The transfer of 1-(2-ethoxyethyl)-2-(4-methyl-l-homopiperazinyl)benzimida e zole difumarate (KB-2413) to the fetus and milk was studied in pregnant and nursing rats, respectively, after oral administration of KB-2413-14C.
We have previously reported the absorption , distribution and excretion of the radioa ctivity after single or multiple oral administration of "C-labelled 1-(2-ethoxyethyl)-2-(4 methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413), a new antiallergic agent , to male rats or guinea pigs''". However, no data are available on the transfer of KB 2413 and/or its metabolites to the fetus and milk in female animals. In the present study , the transfer of the radioactivity to the fetus and milk in female rats after oral administration of KB-2413-"C were investigated. This paper also describes the sex differences in the plasma levels and the influence of the pregnancy on the AUC (area under the plasma concentration-time curve) of KB-2413 in rats.
Experimental Labelled compound-'"C-labelled KB-2413 was identical to that used previously" .
Animals-Female (non-pregnant) rats weighing about 180g and pregnant rats weighing about 220g of Wistar strain (specific pathogen-free) were purchased from Shizuoka Laboratory Animal Center. Nursing rats weighing about 200g were obtained after the delivery of pregnant rats in our laboratory . The diet and environmental condi tions were the same as those described previously". Non-pregnant and pregnant rats were fasted for 16h prior to dosing and for 4 h post dosing. Nursing rats were not fasted before and during the experiment. Pregnant rats were given KB-2413-'"C on the 19th day of the gestation, and nursing rats on the 11 th day after the delivery . For the measurement of plasma levels, animals were cannulated into the right external jugular vein one day before the experiment as previously reported". In the study on the transfer to the milk, nursing rats were separated from sucklings and given oxitocin (Atonin®-O , Teikokuzoki Pharmaceutical Co., Ltd.) intraperitoneally at a dose of 0. 5 U/kg , at 2 h and 1 h before the collection of the milk sample, respectively, and housed together with suck lings after the collection.
Administration of the drug-The labelled KB-2413 was diluted with the non labelled KB-2413 and prepared as a solution in deionized water. KB-2413-'"C was admini stered orally to rats by gastric intubation at a dose of 1 mg/kg (100ItCi/kg) for the whole-body autoradiography and 1 mg/kg (50 pCi/kg) for the other studies . All the volumes of the solution administered were about 2. 5 ml/kg.
Plasma levels-After dosing to pregnant and non-pregnant rats , blood samples were collected at 5, 10, 15, 30 min, 1, 2, 4, 6, 9, 12 and 24 h from the cannulae . The radio activity in plasma was measured according to the method which was described in the previous report". Whole-body autoradiography-At 2, 6 and 24h after the single oral administration to pregnant rats, the whole-body antoradiography was performed as in the previous report" .
Tissue levels-The radioactivity in the maternal and fetal tissues was measured 0.5, 2, 6, 24 and 48h after single oral administration to pregnant rats . The determination of the radioactivity in each tissue was carried out by the same way as described previ ously". Three fetuses from each pregnant rat were used for the measurement of the radioactivity in the fetus homogenate.
Transfer to the milk-Milk samples (about 100 ul) were collected from the nipple by pressing them under light ether anesthesia 1, 2 , 4, 8 and 24 h after the oral admini stration to nursing rats. The duration of each sampling was approximately 10 min . Imme diately after sampling the milk, blood samples (about 120111) were obtained from the tail vein. Then the radioactivity concentration in the milk and plasma was measured .
Determination of the radioactivity-The radioactivity of each sample was measured according to the previous report".
Calculations-KB-2413 was given as the difumarate salt, and concentrations in plasma were expressed as ng equivalent of KB-2413 base.
The elimination half-life (t112) and the area under the plasma concentration-time curve (AUCo-_) were calculated as previously reported". All data were tested for statistically significant differences using Students' t-test in case of 2 groups , or F-test and Tukey's test in case of 3 groups.
Results

Distribution
in pregnant rats Plasma levels : Fig. 1 shows the plasma levels of the radioactivity after oral admini stration of KB-2413-'"C to pregnant and non-pregnant rats . The maximum plasma level (Cmax) appeared 30 and 10 min after dosing in pregnant and non-pregnant rats, respectively. And the secondary peak was observed at 6 h in each rat . Calculated pharmacokinetic parameters of KB-2413-"C in non-pregnant, pregnant and in male rats' are summarized in Table I . The Cax in non-pregnant and the AUC in pregnant rats were higher than those in male rats, and the AUC in pregnant rats was larger than that in non-pregnant rats. But no difference in t1/2 was observed between these three groups of rats.
Whole-body antoradiography : Fig. 2 shows the whole-body autoradiograms prepared 2, 6 and 24 h after oral administration of KB-2413-'4C in pregnant rats. At 2 h, the radi oactivity was detected in the gastrointestinal contents, liver and kidney of maternal rats.
The radioactivity in the placenta and fetuses was fairly low. Heterogenous distribution of the radioactivity was noted in the liver of maternal rats as well as in the liver of male rats2). Two hours after administration the radioactivity was not detectable in the fetal intestine but was found at 6h. At 24h, the radioactivity in the fetal intestine was lower than that at 6 h.
Tissue level : The tissue levels of the radioactivity and its percent distribution 0.5, 2, 6, 24 and 48h after oral administration of KB-2413-"C are summarized in Tables II and   III , respectively. The maximum levels of the radioactivity in the blood, plasma and liver of maternal rats were observed at 0. 5 h after dosing while in other maternal and fetal tissues the maximal concentrations of radioactivity were observed at 2h. At 2h, tissue levels were high in the liver, kidney and lung, and low in the brain, amniotic fluid, blood and plasma in maternal body. In fetuses, the concentration in the liver and intestine were higher than those in the blood and brain 2 h after dosing. At that time, the radio activities found in a fetus and all fetuses were about 0. 1 and 1 % of the dose, respectively, and the ratio of the concentration in fetal homogenate to maternal plasma concentration was 0.84±0.58.
At 48 h, the concentration of the radioactivity in each tissue, except the amniotic fluid and fetal intestine, was reduced to less than 4 % of the maximum level in each tissue.
Transfer to milk Table IV shows the concentrations of the radioactivity in plasma and milk and ratios of milk-to-plasma concentration (M/P ratio) after oral administration of KB-2413-"C to nursing rats. The milk levels were lower than the plasma levels up to 8 h after dosing.
At 24h, the milk levels were about 4 times higher than the plasma levels. The elimination half-life with the milk was found to be 16 h. 
Discussion
The maximum level of the radioactivity in the tissues of fetal rats was reached at 2 h after dosing, and the concentration of the radioactivity in the fetal homogenate was com parable to that in the maternal plasma ( Table  II) . At that time, the radioactivity was high in the liver and kidney, and low in the brain, amniotic fluid, blood and plasma in maternal rats. The radioactivity in the fetal liver and intestine was relatively high (Table   II) , therefore, it seemed that the radioactivity was transfered to bile in fetuses as well as in male rats''.
The experimental data, collected from the nursing rats, showed that the M/P ratios gradually increased, and were 0.81 at 8 h and 4.40 at 24h after drug administration (Table IV) . This might be due to the slow transport of the radioactivity from the plasma to the milk and from the milk to the plasma, and/or the slow formation of the metabolites which could be transported to the milk. The radioactivity was eliminated from the milk with half-life of about 16h.
Appearance of the secondary plasma peak (Fig. 1) , heterogeneous distribution of the radioactivity in the liver (Fig. 2) , high distribution of the radioactivity in the liver and kidney, and low distribution in the central nervous system and fat (Fig. 2 , Table II) were observed in pregnant and/or non-pregnant rats. These phenomena were also noted in male rats as previously reported' 2).
The Cmax and AUC in non-pregnant and pregnant rats, respectively, were significantly larger than those in male rats (Table I ). The sex-related differences in drug metabolism have been widely investigated in rats'-". The difference observed in the present study might be due to the sex-related difference in the metabolism. It is necessary to study the metabolism of KB-2413 in male and female rats.
The AUC in pregnant rats was larger than that in non-pregnant rats (Table I) . It has been reported that the pharmacokinetics of many drugs are affected by pregnancy, for example, the distribution volume and plasma clearance (Dose/ AUC) of many drugs inc rease in human pregnancy". Further study will clarify the effect of pregnancy on the biological fate of KB-2413 in rats.
